Published online 19 February 2009
Haematologica, Vol 94, Issue 4, 594-596 doi:10.3324/haematol.2008.002923
Copyright © 2009 by Ferrata Storti Foundation
Jolanta B. Perz1 ,
Ute Hegenbart1 ,
Nicolaus Kroeger2 ,
Gerd Otto3 ,
Anthony D. Ho1 ,
Peter Dreger1
Haematologica, Vol 94, Issue 4, 594-596 doi:10.3324/haematol.2008.002923
Copyright © 2009 by Ferrata Storti Foundation
Myeloproliferative Disorders |
Successful unrelated donor stem cell transplantation for advanced myelofibrosis in an adult patient with history of orthotopic liver transplantation
1 Department of Medicine V, University of Heidelberg
2 Bone Marrow Transplantation Unit, University of Hamburg
3 Department of Liver Transplant Surgery, University of Mainz, Germany
Correspondence: Jolanta B. Perz, University Heidelberg Internal Medicine, Department of Hematology/Stem Cell Transplantation Unit, Im Neuenheimer Feld 410, 69115 Heidelberg, Germany. Phone: international +49.6221568009. Fax: international +49.6221565721. E-mail:Jolanta.Dengler{at}med.uni-heidelberg.de
Key words: unrelated donor, stem cell transplantation, orthotopic liver transplantation.
Patriarca et al.1 recently reported a significant improvement in outcome of patients with myelofibrosis (MF) after allogeneic stem cell transplantation (SCT). Some MF patients present to the transplant center with severe complications after a long disease history and their treatment may be very challenging.
In 1987, a 33-year old woman was diagnosed with polycythemia vera (PV) associated with portal and splenic vein thrombosis. A year later she developed acute Budd-Chiari syndrome and required orthotopic liver transplantation. In 2002, 15 years since diagnosis, PV progressed to MF. Molecular genetics revealed heterozygous V617F mutation in the Janus Kinase 2 (JAK 2) gene. In 2006, blood count showed: leukocytes 1.5 x 109/L, hemoglobin 8.1 g/dL, platelets 124 x 109/L and 13% circulating blasts. Blood transfusions were required every eight weeks. According to the Lille Scoring System the patient was at high risk of progression to acute leukemia. Since she had no siblings, we decided to start an unrelated donor search, although very few reports exist on allogeneic SCT in patients after preceding solid organ, respectively liver, transplantation. A compatible donor with a single human leukocyte antigen (HLA) Cw mismatch was identified. Patient and donor were mismatched for blood group and cytomegalovirus serology. In April 2007 allogeneic SCT following treosulfan (30 g/m2), fludarabine (150 mg/m2) and anti-thymocyte globuline (ATG 30 mg/kg, Fresenius Biotech, Germany) conditioning was performed. Graft versus host disease (GvHD) prophylaxis consisted of cyclosporine A and mycophenolate mofetil. Engraftment was achieved rapidly. The first 100 days after SCT were complicated by an asymptomatic CMV reactivation and probable viral encephalitis with lymphocytic pleocytosis in spinal fluid and meningeal MRI enhancement but without positive virology findings. Both episodes were successfully treated with foscarnet. As a further complication, syndrome of inappropriate secretion of antidiuretic hormone (SIADH) occurred. Acute GVHD or veno-occlusive disease (VOD) did not occur and liver function remained stable. From day 100 onwards, polymerase chain reactions (PCR) of peripheral blood samples were negative for the JAK2 gene mutation consistent with complete molecular remission of MF. Also sustained complete donor chimerism was confirmed by molecular studies. Bone marrow biopsy at day 100 showed a normal hematopoiesis without signs of fibrosis. Imunosuppression was reduced but the patient remained on low-dose cyclosporine A and prednisone as prior to SCT. A biopsy proven chronic scleroderma GvHD of the skin developed eight months after SCT and mycophenolate mofetil was re-started. Sicca symptoms, persistant cachexy and senso-motoric polyneuropathy developed in the following few months. Eighteen months after SCT the blood count showed: leukocytes 4.0/nL, hemoglobin 13.7 g/dL, platelets 112 x 109/L.
In MF allogeneic SCT is the only treatment modality with the potential to provide prolonged disease control or even cure, whereas conventional treatment results are usually disappointing. Recent reports showed hematologic response in up to 100% and complete histopathological remission in 75% of patients with MF who underwent allogeneic SCT.2,3 High rates of molecular remission are achievable in JAK2-positive patients.4 The feasibility of allogeneic bone marrow transplantation (BMT) from a sibling donor following cadaveric liver transplantation has been demonstrated in a pediatric patient with severe aplastic anemia (SAA) following non-A, non-B, non-C (NANBNC) hepatitis.5 Also long-term follow-up after sibling donor BMT for SAA following orthotopic liver transplantation for hepatitis was reported in another pediatric patient.6 Combined cord blood and haplo-identical BMT for SAA after living-related liver transplantation from the same donor was proposed as an option for children with liver failure due to diseases that can be cured by allogeneic SCT.7 A single case of an adult 29-year old patient with SAA, who received myeloablative conditioning for sibling allogeneic BMT four months after orthotopic liver transplantation for NANBNC hepatitis, has been reported.8,9 Severe acute GvHD of the liver was not observed in any of these cases.5–8 It has been suggested by studies in mice and humans that the liver is the most capable of inducing tolerance after solid organ transplantation due to high leukocyte content, particularly due to the antigen-presenting dendritic cells and their progenitors that migrate from the liver into peripheral blood and tissues, modulate immune responsiveness and induce immunological tolerance.10 In this case we could not detect liver-donor derived leukocyte microchimerism for technical reasons after cadaveric liver transplantation. We postulate that microchimerism after solid organ transplantation might facilitate engraftment and prevent GvHD, but further studies are necessary in this field. To our knowledge this is the first report of a successful reduced intensity conditioning allogeneic SCT from an unrelated donor in an adult patient with a history of liver transplantation. This case might encourage physicians to propose allogeneic SCT to patients with hematologic diseases, who had previous liver or other solid organ transplantations.
References
 TOP References |
|---|
- Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2008;93:1514-22.
[Abstract/Free Full Text] - Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, et al. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 2007;35:1719-22.[CrossRef][Web of Science][Medline]
- Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007;13:355-65.[CrossRef][Web of Science][Medline]
- Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M, et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007;109:1316-21.
[Abstract/Free Full Text] - Kawahara K, Storb R, Sanders J, Petersen FB. Successful allogeneic bone marrow transplantation in a 6.5-year-old male for severe aplastic anemia complicating orthotopic liver transplantation for fulminant non-A-non-B hepatitis. Blood 1991;78:1140-3.
[Abstract/Free Full Text] - Perkins JL, Neglia JP, Ramsay NK, Davies SM. Successful bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation: long-term follow-up and outcome. Bone Marrow Transplant 2001;28:523-6.[CrossRef][Web of Science][Medline]
- Matthes-Martin S, Peters C, Königsrainer A, Fritsch G, Lion T, Heitger A, et al. Successful stem cell transplantation following orthotopic liver transplantation from the same haploidentical family donor in a girl with hemophagocytic lymphohistiocytosis. Blood 2000;12:3997-9.
- Dugan MJ, Rouch DA, Akard LP, Sperl BG, Black JR, Markham RE Jr, Jansen J. Successul allogeneic bone marrow transplantation in an adult with aplastic anemia following orthotopic liver transplantation for non-A, non-B, non-C hepatitis. Bone Marrow Transplant 1993;12:417-9.[Web of Science][Medline]
- Chiang KY, Lazarus HM. Mini review. Should we be performing more combined hematopoietic stem cell plus solid organ transplants?. Bone Marrow Transplant 2003;31:633-42.[CrossRef][Web of Science][Medline]
- Thomson AW, Lu L, Murase N, Demetris AJ, Rao AS, Starzl TE. Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells 1995;13:622-39.[Web of Science][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||